Press releases
- Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®
- Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®
- Calliditas Therapeutics to Attend Investor Conferences in March
- Calliditas Year-end report, January - December 2023
- Invitation to the presentation of Calliditas´ Year-end report January - December 2023
- Calliditas provides patent update
- Calliditas Therapeutics provides business update ahead of JP Morgan conference
- Calliditas Therapeutics appoints Maria Törnsén as President North America
- Calliditas to present at JP Morgan Healthcare Conference
More ▼
Key statistics
On Thursday, Calliditas Therapeutics AB (LC8:STU) closed at 9.78, 40.22% above the 52 week low of 6.98 set on Sep 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.96 |
---|---|
High | 9.96 |
Low | 9.78 |
Bid | 9.78 |
Offer | 9.88 |
Previous close | 9.94 |
Average volume | 0.00 |
---|---|
Shares outstanding | 59.58m |
Free float | 49.57m |
P/E (TTM) | -- |
Market cap | 6.76bn SEK |
EPS (TTM) | -8.69 SEK |
Data delayed at least 15 minutes, as of Mar 28 2024.
More ▼